HilleVax (HLVX) Tanks as Norovirus Vaccine Study in Infants Fails

The double-blind, placebo-controlled study evaluated the efficacy, safety and immunogenicity of HIL-214 in infants around five months old. Shares of the company were down 88.3% on Jul 8 following the announcement of the news. The stock has plunged 89.8% so far this year compared with the industry's decrease of 7.9%. HilleVax, Inc. (HLVX) announced that its phase IIb NEST-IN1 study, evaluating its investigational virus-like particle-based vaccine candidate, HIL-214, in infants for the prevention of acute gas ...